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Abstract
Runt domain transcription factor 3 (RUNX3) is widely regarded as a tumour-suppressor gene 
inactivated by DNA hypermethylation of its canonical CpG (cytidine-phosphate-guanidine) island 
(CGI) promoter in gastric cancer (GC). Absence of RUNX3 expression from normal gastric 
epithelial cells (GECs), the progenitors to GC, coupled with frequent RUNX3 overexpression in 
GC progression, challenge this longstanding paradigm. However, epigenetic models to better 
describe RUNX3 deregulation in GC have not emerged. Here, we identify lineage-specific DNA 
methylation at an alternate, non-CGI promoter (P1) as a new mechanism of RUNX3 epigenetic 
control. In normal GECs, P1 was hypermethylated and repressed, whereas in immune lineages P1 
was hypomethylated and widely expressed. In human GC development, we detected aberrant P1 
hypomethylation signatures associated with the early inflammatory, preneoplastic and tumour 
stages. Aberrant P1 hypomethylation was fully recapitulated in mouse models of gastric 
inflammation and tumorigenesis. Cell sorting showed that P1 hypomethylation reflects altered 
cell-type composition of the gastric epithelium/tumour microenvironment caused by immune cell 
recruitment, not methylation loss. Finally, via long-term culture of gastric tumour epithelium, we 
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revealed that de novo methylation of the RUNX3 canonical CGI promoter is a bystander effect of 
oncogenic immortalization and not likely causal in GC pathogenesis as previously argued. We 
propose a new model of RUNX3 epigenetic control in cancer, based on immune-specific, non-CGI 
promoter hypomethylation. This novel epigenetic signature may have utility in early detection of 
GC and possibly other epithelial cancers with premalignant immune involvement.
INTRODUCTION
Gastric cancer (GC) has the second highest rate of cancer-related mortality worldwide, 
accounting for >700 000 deaths annually.1 Late diagnosis is a major challenge to GC 
management, with disease presentation typical at advanced stages when treatment is 
ineffective and prognosis is poor.2 Chronic inflammation after infection with Helicobacter 
pylori is a primary risk factor for the most common or ‘intestinal-type’ GC,3 but definitive 
mechanisms remain elusive. GC is believed to be of epithelial origin, deriving from gastric 
epithelial cells (GECs) or their progenitors.4,5 Elucidation of molecular events underlying 
the inflammation-related preneoplastic transformation of GECs3 will be critical for the 
advancement of GC management, allowing earlier disease detection and improved survival.
Aberrant DNA methylation is one of the earliest molecular alterations in cancer and has 
been linked to GC pathogenesis.6,7 Hypermethylated sequences become hypomethylated on 
a global scale. Conversely, unmethylated CpG (cytidine-phosphate-guanidine) island (CGI) 
promoters, including those of some tumour-suppressor genes (TSGs), become 
hypermethylated leading to their repression.8 Hypermethylation of TSGs has been 
traditionally viewed as a persuasive mechanism of cancer pathogenesis, as well as providing 
a target for cancer detection.9 Nonetheless, recent evidence that de novo hypermethylation in 
cancer mostly affects CGI promoters already repressed in normal tissues argues that 
methylation is not always required for their repression and therefore is not necessarily a 
driver of cancer.10 Cell-type composition of the tumour microenvironment has gained 
attention as an alternative influence on cancer methylation profiles.11 In this context, CpG-
depleted or ‘non-CGI’ promoters, which show considerable variation in lineage-specific 
methylation, may offer complementary clinical utility to CGI promoters.12,13 Indeed, the 
prognostic value of methylation signatures corresponding to non-neoplastic tumour lineages, 
such as cancer-associated fibroblasts or cytolytic T-lymphocytes, has recently been 
demonstrated.14,15
Runt domain transcription factor 3 (RUNX3) belongs to the family of conserved ‘runt-
domain’ transcription factors that have diverse roles in hematopoiesis, neurogenesis and 
skeletal development.16–18 RUNX3 transcription initiates from two cis-regulatory regions 
designated the P1 (distal) and P2 (proximal) promoters. Expressed predominantly in 
hematopoietic lineages, RUNX3 regulates several aspects of immune function, including T-
cell differentiation,19,20 dendritic cell (DC) maturation21 and natural killer (NK) cell 
activation.22,23 In contrast to these definitive immune roles, the RUNX3 locus (located on 
human chromosome 1p36.1) has been controversially linked to a TSG function in GC. In 
2002, Li et al.24 proposed that RUNX3 inactivation via hypermethylation of a large CGI 
overlapping its P2 promoter is a pivotal event in GC pathogenesis. Subsequent studies have 
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confirmed the association of RUNX3 P2 hypermethylation with GC incidence (reviewed in 
Fan et al.25 and Subramaniam et al.26). However, fresh evidence that RUNX3 is never 
expressed in the normal GEC from which GC originates27 casts doubt not only on its 
proposed TSG function, but also on the role of P2 methylation in RUNX3 silencing and its 
associated utility as a functional marker of GC. Limitations of this widely disseminated 
epigenetic model24 are further compounded by paradoxical observations of RUNX3 
overexpression in GC and other cancers28–30 where P2 is reportedly hypermethylated.31 
Although RUNX3 continues to feature in the literature, models to better explain its 
deregulation in cancer have not emerged. With its TSG function now disputed,27 unravelling 
the inconsistencies of RUNX3 epigenetic control in GC will lead to an improved 
understanding of its broader role in cancer biology.
In focussing exclusively on the mechanistic importance of P2 methylation, researchers have 
overlooked a role for the alternate ‘non-CGI’ RUNX3 P1 promoter. Here we address this gap 
in understanding, showing that lineage-specific P1 methylation constitutes a novel and 
unexpected mechanism of RUNX3 epigenetic control in GC. We find that, in normal GEC, 
P1 is strongly hypermethylated and repressed. By striking contrast, in immune lineages, P1 
is hypomethylated and widely expressed. Through studies of human and mouse GC 
progression, we uncover a preneoplastic P1 hypomethylation signature reflecting altered 
cell-type composition of the gastric epithelium/tumour microenvironment via immune cell 
infiltration. Finally, we reveal that de novo methylation of the P2 CGI promoter in GEC, 
argued previously as a driver of GC pathogenesis, arises as a bystander effect of oncogenic 
immortalization and is unlikely to exert any significant impact on GC progression. These 
results delineate a novel, more parsimonious model of RUNX3 epigenetic control with 
emphasis on lineage-specific P1 methylation as a marker of preneoplastic tissue 
remodelling. The strong translational relevance of our findings to GC, and potential 
application to other epithelial cancers of inflammatory provenance, is discussed.
RESULTS
RUNX3 P1 hypomethylation correlates with human GC progression
To date, all RUNX3 methylation studies have targeted the CGI overlapping the P2 promoter, 
but none have interrogated P1 methylation in GC (Figure 1a). The P1 sequence falls short of 
the minimum CpG density criteria to qualify as a CGI (CpG observed/expected ratio >40.6; 
>200bp32) and is therefore ‘non-CGI’-associated. In contrast to CGI promoters that 
generally resist methylation, non-CGI promoters are very likely to be regulated by 
methylation if CpG dinucleotides are present.12,33 Indeed, this is the case for the human and 
mouse P1 sequences (Supplementary Figure S1). We therefore investigated RUNX3 P1 
expression and methylation in human gastric epithelial tissue collected from individuals 
displaying early-, intermediate- or late-stage intestinal-type GC development: H. pylori-
infected/gastritis,34 intestinal metaplasia (IM) and GC, respectively,6 together with normal 
(disease-free) controls (Figure 1b). Quantitative reverse transcriptase–PCR (QRT–PCR) 
revealed increased total RUNX3 mRNA expression in H. pylori-infected (4.05 ± 0.60-fold; P 
< 0.001), IM (8.47 ± 3.04-fold; P < 0.01) and GC (2.54 ± 0.73-fold; P < 0.01) tissues 
relative to normal controls (Figure 1c). Specific measurement of P1 mRNA similarly 
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revealed increased expression in H. pylori-infected (8.77 ± 1.74-fold; P < 0.001) but not in 
IM or GC tissues. The high GC content of the P2 transcript 5′ leader exon precluded its 
direct interrogation by QRT–PCR. These results show increased RUNX3 P1 expression, 
particularly during preneoplastic stages of GC. We next examined RUNX3 P1 methylation 
levels using Sequenom EpiTYPER assays. EpiTYPER quantifies the ratio of methylated to 
unmethylated cytosines at individual CpG dinucleotides at specific loci.35 Although P1 
hypermethylation predominated in normal gastric epithelial tissues, a P1 hypomethylation 
signature was significantly associated with H. pylori-positive, IM and GC tissues. Consistent 
with its CGI status, P2 remained unmethylated in H. pylori-infected and IM preneoplastic 
tissues, showing modestly increased methylation only in a subset of tumours but not 
exceeding 15% (that is, methylation ratio 0.15) of strands in any individual tumour (Figure 
1d). Hierarchical clustering showed a clear association of P1 hypomethylation with early 
inflammatory, preneoplastic and tumour stages of GC. Conversely, P2 was less vulnerable to 
epigenetic perturbation, showing weak hypermethylation in a subset of tumours (Figure 1e). 
RUNX3 P1 and P2 are thus oppositely methylated in normal gastric tissue, respectively 
showing uniform early loss and variable late gain of methylation in GC progression. These 
results identify RUNX3 P1 hypomethylation as a novel epigenetic signature with potential 
utility in GC risk prediction.
Conserved Runx3 P1 hypomethylation following H. pylori infection, genetic induction of 
gastric inflammation or tumorigenesis in mice
Human and mouse RUNX3/Runx3 are highly conserved with respect to their genomic 
organization, dual promoter structure (Figure 2a) and tissue expression profile. Therefore, 
mouse genetic and infection models recapitulating H. pylori-related preneoplastic and 
tumorigenic stages of human GC progression (Figure 2b), offered the most stringent 
approach to pinpoint the origin and significance of RUNX3 P1 hypomethylation in vivo. 
Accordingly, we first determined Runx3 transcription and methylation in stomachs of 
C57BL6 (wild type; WT) mice infected with mouse-adapted H. pylori SS1 for either 3- or 
12 months. QRT–PCR showed that P1 and P2 transcripts were progressively upregulated in 
3-month (4.10 ± 1.08; P = 0.036 and 12.58 ± 3.00; P = 0.008) and 12-month (8.22 ± 1.43-
fold; P = 0.005 and 66.59 ± 12.28-fold; P < 0.001) infected mice compared with uninfected 
littermate controls (Figure 2c). Similar to our observations in H. pylori-infected humans, 
aberrant P1 hypomethylation was evident in H. pylori-infected mice, showing progression 
from a moderate to a strong signature in 3- and 12-month infected mice, respectively. 
Conversely, P2 methylation was unaltered with H. pylori infection (Figures 2d and e). To 
discern effects of H. pylori-dependent inflammation versus bacterial presence on P1 
hypomethylation, we utilized transgenic mice with stomach-specific overexpression of the 
pro-inflammatory cytokine, gmcsf, (gmcsfTg). GmcsfTg mice develop spontaneous gastric 
inflammation independently of H. pylori infection.36 Runx3 P1 transcripts were upregulated 
(2.58 ± 0.31-fold; P < 0.01) in gmcsfTg compared with WT stomachs (Figure 2c) and 
correlated with P1 hypomethylation (Figures 2d and e). P2 was not differentially expressed 
or methylated (Figures 2c and e). Therefore P1 hypomethylation correlates with gastric 
inflammation, not with H. pylori’s presence per se. To determine whether P1 
hypomethylation persists later in GC progression, we utilized the gp130F/F GC model.37 
Gp130F/F mice develop tumours of the distal stomach with similar histopathology to human 
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GC. Though epithelial in origin, gp130F/F tumours are strongly infiltrated by cells of the 
innate and adaptive immune system. Increased P1 transcription (9 ± 1.46-fold; P < 0.05) 
(Figure 2b) and P1 hypomethylation were clearly correlated in gp130F/F tumours (Figures 2c 
and d), further supporting a link with gastric inflammation. Conversely, P2 transcription was 
increased (23.19 ± 6.10-fold; P<0.01) independently of its methylation status (Figures 2b 
and d). These results show that aberrant RUNX3 P1 hypomethylation is a conserved, 
inflammation-associated process correlating with the preneoplastic and tumorigenic stages 
of GC.
RUNX3 localizes to infiltrating immune cells and not to epithelial cells in gastric 
preneoplasia and cancer
RUNX3 was localized in H. pylori-infected (n = 16) and uninfected (n= 6) human gastric 
tissues by immunohistochemistry. RUNX3-specific staining was detected in nuclei of 
immune cells infiltrating the lamina propria of H. pylori-infected but was not detected in 
uninfected tissues (Figure 3a). RUNX3 was not detected in GECs of infected or uninfected 
individuals. We similarly analysed the stomachs from gmcsfTg and gp130F/F mice. In 
gmcsfTg mice, RUNX3-specific staining localized to the nuclei of immune cells infiltrating 
the gastric epithelium but was not detected in GECs (Figure 3b). Similarly, in gp130F/F 
mice, RUNX3 was detected in immune cells infiltrating lamina propria of antral tumours 
and in submucosal lymphoid pockets but was not detected in GECs (Figure 3c). Earlier work 
showed absence of RUNX3 in normal mouse intestinal epithelium;27 however, our results 
make the novel and critical distinction of showing absence of RUNX3 in normal, 
preneoplastic and tumour gastric epithelium in both humans as well as in mice. Therefore, 
RUNX3 overexpression in gastric preneoplasia and cancer is likely dependent on immune 
cell recruitment.
Differential Runx3 P1 methylation in GECs and immune lineages
Runx3 is known to be highly expressed in immune lineages (Supplementary Figure S2). 
Localization of gastric RUNX3 to infiltrating immune cells suggested that altered P1 
methylation could similarly reflect immune cell recruitment. To address this, we isolated 
immune lineages known to have high Runx3 expression: NK1.1+CD3− NK cells, CD8+ T-
cells, CD11c+ DCs, or low/absent Runx3 expression: CD11b+ macrophages, Gr1+ 
neutrophils, and CD45R+ B-cells from the spleens of WT mice by fluorescence-activated 
cell sorting (FACS) (Figure 4a; Supplementary Figure S3) and characterized their Runx3 
mRNA and methylation profiles relative to primary GECs. Runx3 P1 transcripts were 
detected in all immune cell types except B-cells, being most abundant in NK cells, CD8+ T-
cells and DCs. P2 transcripts were abundant only in NK cells, showing modest levels in 
other lineages and were absent in GECs (Figure 4b). Strikingly, P1 was hypomethylated in 
all immune cell types irrespective of their Runx3 expression level. This suggests that P1 
hypomethylation is permissive but not sufficient for transcription. Conversely, P1 was 
hypermethylated in primary GECs and mouse embryonic fibroblasts, which lack Runx3 
expression (Figure 4c). By reference to the public domain transcriptome data, mast cells 
(MCs) were noted for abundant Runx3 mRNA expression (Supplementary Figure S2) but 
have otherwise not been formally described to express Runx3. Analysis of spleen-derived, c-
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kit/CD117+FcεR1 + MCs (Figure 4a) confirmed Runx3 P1 hypomethylation and 
transcription at similar levels to CD8+ T-cells (Figures 4b and c).
Our results showing universal P1 hypomethylation in immune cells suggested that its 
specific epigenetic state might originate before, or during, hematopoiesis. To address this 
question, we tracked P1 methylation levels during MC differentiation from mouse bone 
marrow stem cells (BMSCs) cultured with interleukin (IL)-3. Correct MC differentiation 
was verified by the acquisition of a c-kit/CD117+FcεR1α+ surface phenotype (Figure 4d) 
and induction of carboxypeptidase (Cpa3) mRNA (Supplementary Figure S3). Bone 
marrow-derived MCs showed strong induction of Runx3 P1 mRNA relative to BMSCs 
showing only marginal expression, while P1 was equivalently hypomethylated in BMSCs 
and differentiated MCs (Figures 4e and f). Similar results were obtained in bone marrow-
derived DCs (B Kurklu, unpublished data). These results argue that immune-specific P1 
hypomethylation is inherited from BMSCs, further suggesting the existence of a 
developmental mechanism that protects P1 against de novo methylation in certain contexts.
Immune cell recruitment accounts for Runx3 P1 hypomethylation in gastric epithelial 
tumours
We next examined P1 methylation in GECs and immune cells isolated directly from 
gp130F/F gastric tumours. Dissected tumours were non-enzymatically disaggregated, and the 
following cell types were recovered by FACS: e-cadherin+ GECs, CD8+ T cells, and 
CD11c+ DCs (Figure 5a). EpiTYPER analysis of these tumour cell fractions revealed that 
P1 hypomethylated alleles were enriched in CD8+ T-cells and CD11c+ DCs. Conversely, P1 
hypermethylated alleles were enriched in e-cadherin+ GECs. P2 was unmethylated in 
tumour-derived immune cells and GECs (Figures 5b and c). That is, hypomethylated P1 
alleles reside predominantly within the immune, but not the epithelial component of gastric 
tumours, supporting immune cell recruitment as a key mechanism underlying a RUNX3 P1 
hypomethylation signature in GC progression.
Runx3 P2 hypermethylation triggered by immortalization of GECs
RUNX3 P2 hypermethylation clearly has no direct role in RUNX3 repression or as an 
autonomous driver of GC; however, its significance remains unexplained. Cancer-related de 
novo methylation targets repressed CGI promoters,10,38 and this global deregulation of 
methylation may arise as an effect of cellular immortalization.38 Immortalized cell lines 
often show more extensive CGI hypermethylation than corresponding primary tumours.39 
Accordingly, we compared P2 methylation levels in immortal human GC cell lines and 
primary GC tissues. Five out of the six cell lines showed near complete (>90%) P2 
hypermethylation (Figure 6a) contrasting with much lower levels (<15%) in primary GC 
tumour tissues. The single exception was the slow growing NCI-N87 line, which showed 
only marginally increased P2 methylation levels. P1 methylation levels were similar in both 
normal, tumour and cell lines. These results reveal a specific correlation between 
hypermethylation of the P2 CGI and GEC immortalization. To explore this concept, we next 
quantitated P2 methylation levels in mouse GECs both before and after their 
immortalization in vitro. Immortalization, defined as the inappropriate acquisition of 
indefinite proliferation, was induced by serial passage of cultured primary GECs isolated 
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from gp130F/F gastric tumours (Figure 6b). We cloned five GEC lines showing key features 
of an immortalized phenotype, including a high level of aneuploidy and the capacity to 
proliferate indefinitely in culture. Additionally, two of the lines displayed anchorage-
independent growth in soft agar, yet all of the lines retained expression of key epithelial 
marker proteins, including cytokeratin (Krt)8 (Figures 6c and d; Supplementary Table S1). 
Though derived from primary GECs lacking P2 methylation, four of the five GEC lines had 
acquired high-level P2 hypermethylation after immortalization (Figure 6e). P2 methylation 
levels were the highest in the fastest growing lines (clones1, 3 and 5), whereas only minor 
gains in methylation were observed in the slowest growing line (clone 2). Conversely, P1 
methylation in the immortal GECs was unperturbed relative to normal GECs (Figure 6e), 
consistent with evidence that de novo methylation in epithelial carcinogenesis may 
specifically target repressed CGI promoters. Therefore, P2 hypermethylation can be induced 
during GEC immortalization, likely in concert with de novo hypermethylation of other CGI 
promoters on a global scale. The over-representation of P2 hypermethylation among GC cell 
lines argues that CGI hypermethylated GEC clones may have a growth advantage, resulting 
in their preferential expansion in culture.
DISCUSSION
This work is the first to reveal a role for RUNX3 P1 promoter methylation in regulating 
lineage-specific RUNX3 transcription in the stomach. We specifically showed that P1 
methylation is established differently in GEC and immune cells and that increased 
recruitment of the latter underlies aberrant P1 hypomethylation in GC progression. Finally, 
we showed that de novo methylation of the P2 CGI promoter in GEC/tumour cells, argued 
previously as a driver of GC progression, likely arises as a bystander effect of oncogenic 
immortalization and is unlikely to have a causal role in the disease. We surmise that an in 
vitro growth advantage, associated with global CGI promoter hypermethylation, leads to an 
over-representation of hypermethylated P2 alleles in immortal GC cell lines. Our novel 
findings are summarized in Figure 7.
More than a decade has passed since Li et al.24 initially described RUNX3 as a TSG 
repressed by P2 hypermethylation in GC. Then recognized as a significant advance, the 
findings engendered a long-standing paradigm of gastric tumorigenesis via TSG epigenetic 
loss. Frequent P2 hypermethylation in GC and other cancers remains undoubted, having 
been verified by hundreds of subsequent studies seeking to replicate and extend the 
pioneering work of Li et al. (reviewed in Fan et al.25 and Subramaniam et al.26). However, 
the demonstrable absence of RUNX3 from normal GECs, the progenitors to GC, casts doubt 
upon its much vaunted TSG function.27 By inference, the existing model of P2 
hypermethylation as a driver of GC is also inadequate given that RUNX3 is repressed by 
default in normal GECs and is often overexpressed in GC and other cancers.
We propose an alternative model in which differential methylation of P1 dictates lineage-
specific RUNX3 expression. This novel modality was evident from observations in normal 
GEC and mesenchymal (fibroblast) lineages, where P1 was hypermethylated and repressed. 
By contrast, in immune lineages P1 lacked methylation and was widely transcribed. The fact 
that not all immune cell types have Runx3 expression, despite their universal P1 
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hypomethylation, argues that trans-factors are also required for full activation of 
transcription. This mode of differential methylation was highly significant in the context of 
human and mouse GC progression. P1 hypomethylation (and increased transcription) 
signatures reflected evolving cell-type composition of the preneoplastic epithelium and/or 
tumour microenvironment due to immune cell recruitment. Moreover, localization of 
RUNX3 to immune cells infiltrating the preneoplastic and tumour epithelium as shown here 
excludes the possibility that preneoplastic epithelial lesions, such as atrophic gastritis or 
mucous cell metaplasia, may have influenced P1 transcription and/or methylation. In breast 
cancer, DNA methylation profiles reflecting the tumour immune component have been used 
to great effect for clinical prediction.14 Presence of T-cell ‘methylation biomarkers’ in breast 
tumours correlated with better prognosis, suggesting a link with anti-tumour immunity. We 
postulate that RUNX3 P1 hypomethylation, as a marker of cytotoxic lymphocytes, may have 
similar prognostic value in GC, a postulate supported by the fact that cytolytic properties of 
CD8+ T-cells and NK cells are Runx3-dependent.23
A second major conclusion here is that P2 hypermethylation is a phenotypic feature of 
transformed, or immortal, GECs and has no causal role in RUNX3 repression or GC 
pathogenesis. Our findings are reminiscent of recent work in hTERT-immortalized 
fibroblasts showing progressive accumulation of P2 hypermethylation as a function of 
increasing generations in culture, without affecting transcription.40 However, our findings 
make the key distinction of showing evolution of immortal P2 hypermethylated clones from 
primary GECs ostensibly lacking P2 methylation. Whether P2 hypermethylation can arise de 
novo in culture, or amplifies clonally from rare aberrant cells in primary tumours, remains to 
be elucidated. Resonant with our findings, repressed CGI promoters are more vulnerable to 
de novo methylation in cancer than active CGI promoters10,38 based on polycomb-mediated 
premarking by repressive histone (H)3-lysine (K)27 tri-methylation.41 Together with 
evidence that the polycomb repressor complex 2 can promote RUNX3 P2 repression in 
GEC,42 these studies illustrate how a program of DNA methylation-independent repression 
might promote de novo P2 hypermethylation in immortal GECs. Nonetheless, it is 
increasingly apparent that CGI hypermethylation is less frequent in cancer than initially 
hypothesized.43 We indeed observed lower P2 methylation frequencies here using 
quantitative EpiTYPER analysis than reported by earlier studies using nonquantitative 
methylation-specific PCR (MSP).25,26 The propensity of non-quantitative MSP to 
overestimate low methylation levels44 may explain this discrepancy. In agreement, recent 
work found that P2 methylation levels of <10% can be reported as ‘hypermethylated’ by 
MSP.45
With its TSG function now in doubt,27 alternative roles for RUNX3 in the stomach must be 
considered. It has not escaped our notice that gastric epithelial hyperplasia in Runx3−/− mice 
may arise by a non-autonomous mechanism. This phenotype was attributed to Runx3 
deficiency in CD8+ cytolytic T-cells and consequent impairment of anti-tumour 
immunity.46 An immune-specific anti-tumour role was similarly implicated by spontaneous 
colitis and tumour growth in mice with lymphocyte-specific Runx3 deficiency.47 It may be 
significant that Runx3 expression is particularly abundant in immune lineages with known 
roles in anti-tumour immunity. Runx3 is essential for the cytolytic functions of CD8+ T-cells 
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and NK cells,19,23 but if either of these modalities might extend to restrain gastric tumour 
growth remains to be proven.
Here we have proposed a new model of RUNX3 epigenetic control based on lineage-specific 
hypomethylation of its (non-CGI) P1 promoter in immune cells. Furthermore, aberrant 
RUNX3 P1 hypomethylation derives from the mobile immune component of the 
preneoplastic and tumour epithelium during GC development. The significance of this new 
data lies in the potential clinical utility of P1 methylation in identifying ‘at-risk’ individuals 
during the preneoplastic stages of GC, before the emergence of malignant adenocarcinoma. 
P1 methylation may therefore offer superior clinical potential to P2 methylation, which 
appears later in GC progression and, reportedly, has no predictive value in staging, 
prognosis, recurrence or survival.25
MATERIALS AND METHODS
Human tissues
H. pylori-infected and uninfected human gastric epithelial tissues, GCs and preneoplastic 
adjacent to cancer tissues with IM were obtained endoscopically as described.6 Ethics 
approvals were obtained from the Royal Melbourne Hospital Human Research Ethics 
Committee (approval number 2004.176) and the Kanazawa University Ethics Committee for 
Human Genome Research (approval number 174.2008). Written informed consent was 
obtained for all study participants.
Mice
H+/K+ATPase-gmcsf transgenic mice36 were maintained on a Balb/C genetic background. 
Gp130/F/F co-receptor knock-in mice37 were maintained on a C57BL6/J genetic 
background. WT littermate controls were used in all the experiments. Mice were housed 
under specific pathogenfree conditions. Experiments were approved by the Murdoch 
Children’s Research Institute Animal Ethics Committee (approval numbers A693 and 
A713). WT (C57BL6) mice were infected with the H. pylori Sydney strain (SS) 1 as 
described.6
Mammalian cell culture
Human GC cell lines AGS, MKN7, MKN28, NCI-SNU1, KATO III and NCI-N87 were 
cultured in RPMI 1640 Glutamax medium supplemented with 10% fetal bovine serum 
(FBS); 2 mM non-essential amino acids; 50 IU penicillin; 50ug/ml streptomycin (Invitrogen, 
Carlsbad, CA, USA) at 37 °C in a humidified incubator with 5% CO2/air. To derive mouse 
primary GECs, stomachs from 3-week-old mice were chopped into ~1-mm3 pieces and 
digested with 2 mg/ml collagenase A (Roche, Mannheim, Germany) at 37 °C for 1 h. 
Digested tissue was resuspended in Dulbecco’s modified Eagle’s medium Glutamax 
medium supplemented with 20% FBS, 2 mM non-essential amino acids; 50IU penicillin; 
50ug/ml streptomycin (Invitrogen), disaggregated by repeated pipetting, seeded into 24-well 
plates and incubated at 37 °C with 5% CO2/air for 48 h to allow for culture maturation. To 
derive immortal mouse GEC lines, freshly dissected gp130F/F gastric tumours were surface 
sterilized by incubation in 0.04% sodium hypochlorite in phosphate-buffered saline (PBS) 
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for 20 min at room temperature, rinsed in PBS, chopped into ~1-mm3 pieces, resuspended in 
sterile PBS and allowed to settle for 1 min. Supernatants were aspirated, and tissue was 
collected by centrifugation, resuspended in 1 mg/ml collagenase and 1 IU/ml neutral 
protease (Sigma, St Louis, MO, USA) in PBS and digested at 37 °C for 60 min. Digested 
tissue was collected by centrifugation, resuspended in growth medium48 seeded onto 
collagen-coated 24-well culture plates and incubated undisturbed for 7 days. Rapidly 
expanding epithelial clones were isolated from contaminating non-epithelial cells by 
limiting dilution.
Generation of bone marrow-derived cultured MCs
Bone marrow stem cells were extracted from femurs of 6–8-week-old C57BL6 mice and 
cultured in Dulbecco’s modified Eagle’s medium Glutamax medium, supplemented with 
10% FBS, 50 IU penicillin, 50 ug/ml streptomycin and IL-3 for 6 weeks as described.49 
IL-3-enriched medium was sourced from murine WEHI-3 myelomonocytic leukaemia 
cultures and added to growth medium at 20%v/v.50 MC differentiation was verified by cell 
surface staining with CD117-FITC (fluorescein isothiocyanate; 1:300) and FcεR1α-PE 
(1:300; BD Biosciences, San Jose, CA, USA). Stained cells were analysed on a LSR-II flow 
cytometer using the FacsDiva software (BD Biosciences).
Immunohistochemistry and immunofluorescence
Immunohistochemistry with peroxidase detection was done essentially as described.51 A 
well-characterized rabbit polyclonal anti-Runx3 antiserum (poly-G) was used at a dilution of 
1:1000.52 Bound immunocomplexes were detected using Vectastain ABC reagents (Vector 
Laboratories, Burlingame, CA, USA), and staining was visualized by incubation in 3, 3′-
diaminobenzidine tetrahydrochloride buffer (Sigma). Immunofluorescence in cultured cells 
was performed as described.51 A FITC-conjugated rat polyclonal anti-mouse cytokeratin 
(Krt)8 antibody (Sigma) was used at a dilution of 1:100.
FACS
Splenocytes were prepared from 12-week mice, erythrocytes were removed by incubation in 
lysis buffer (1:9 v/v 0.17M Tris: 0.16 M ammonium chloride) for 5 min and enriched 
splenocytes were resuspended in 2% FBS and 1 mM EDTA in Hank’s Balanced Salt 
Solution. For isolation of tumour lineages, dissected gp130F/F gastric tumours were chopped 
into ~3–4mm3 pieces and disaggregated non-enzymatically by incubation in dissociation 
buffer (5% FBS, 1 mM dithiothreitol, 1 mM EDTA in PBS) for 1 h at 37 °C with agitation. 
Digested tissue pieces were passed through a 70-μm strainer, and the cells were resuspended 
in 2% FBS and 2 mM EDTA in Hank’s Balanced Salt Solution. Splenocytes and gastric 
tumour cells were stained with CD11c-APC (1:500), CD8α-APC-Cy7 (1:500), CD45R/
B221-FITC (1:500), CD11b-PE (1:500), Gr-1 (Ly6-G/C)-PerCP-Cy5.5 (1:300) (all from BD 
Biosciences) and NK1.1-brilliant violet 421 (1:300) E-cadherin-PE (1:300) (from 
BioLegend, San Diego, CA, USA). Cells were sorted (at low pressure with a 100-μm 
nozzle) on a MoFlo sorter (Beckman-Coulter, Brea, CA, USA). Cells were not cultured in 
the period between isolation and sorting.
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Gene expression and DNA methylation analysis
QRT–PCR was performed as described.53 Primer sequences (Supplementary Table S2) were 
designed using the primer3 tool (http://frodo.wi.mit.edu/primer3/). Relative gene expression 
was normalized to the reference genes GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase; human) or Rpl32 (mouse) using −2ΔΔCt = ΔCt sample−ΔCt calibrator. 
Quantitative DNA methylation analysis was performed by EpiTYPER (Sequenom, San 
Diego, CA, USA) as described.6 Primer sequences for methylation amplicons 
(Supplementary Table S3) were selected using EpiDesigner (http://www.epidesigner.com). 
Data cleaning and hierarchical clustering were performed in R script using the gplots 
package (http://www.r-project.org/).
Statistical analysis
Data were analysed with GraphPad Prism V5.1 software (GraphPad Software, La Jolla, CA, 
USA). Data were expressed as mean ± s.e.m. Statistical analysis was performed by one-way 
analysis of variance and the appropriate parametric or nonparametric post test. P-values of ≤ 
0.05 were considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
CGI CpG island
CpG cytidine-phosphate-guanidine
DC dendritic cell
GC gastric cancer
GEC gastric epithelial cell
hTERT human telomerase reverse transcriptase
IM intestinal metaplasia
MC mast cell
MSP methylation-specific PCR
NK natural killer
RUNX runt-domain family transcription factor
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Figure 1. 
Epigenetic regulation of RUNX3 P1 in human GC. (a) Mapping of methylation amplicons 
within human RUNX3. Genome browser output for human RUNX3 on chromosome 1p36 
(GRCh37 Hg19; http://genome.ucsc.edu/) shows relative locations of P1 and P2 promoter 
regions and intron/exon structures of the derived transcripts. Browser tracks show locations 
of RUNX3 methylation amplicons (from previously published studies, black bars; from 
current study, red bars) aligned with the human genome using the ‘Blast Like Alignment 
Tool’ (BLAT). (b) Schematic showing progressive alteration in cell-type composition of the 
gastric epithelium during human GC progression. (c) QRT–PCR analysis of RUNX3 mRNA 
expression in human GC progression. Box plots show mRNA fold change relative to 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) internal reference gene expression 
for normal (N; n=6), H. pylori-infected (HP; n = 16), preneoplastic adjacent to tumour with 
intestinal metaplasia (IM; n=28) and gastric cancer (GC; n=28) mucosal tissues. (d) 
EpiTYPER analysis of RUNX3 P1 and P2 methylation in tissue samples analysed in panel 
(b). Box plots show combined CpG methylation values for P1 and P2, respectively. (e) 
Heatmap showing two-way hierarchical clustering of methylation data presented in panel 
(c). CpGs are shown on the horizontal axis; tissue samples are shown on the vertical axis. 
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Tissue identities are indicated to the right of the heatmap. Asterisks show statistical 
significance: **P < 0.01; ***P < 0.001.
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Figure 2. 
Conserved Runx3 P1 hypomethylation in mouse gastric inflammation and tumorigenesis. (a) 
Genome browser output for the mouse Runx3 locus on chromosome 4qD3 (GRCm38/
mm10; http://genome.ucsc.edu/) shows relative locations of P1 and P2 promoters and intron/
exon structure of their transcripts. (b) Schematic showing the mouse genetic and infection 
models used to recapitulate key stages of human GC progression. (c) QRT–PCR analysis of 
Runx3 P1 and P2 transcripts in stomach tissues collected from C57BL6 (WT) mice infected 
with H. pylori SS1 for 3 months (Hp 3m) and 12 months (Hp 12m) in GmcsfTg and gp130F/F 
mice. Histograms show mRNA fold change relative to uninfected or WT controls. (d) 
EpiTYPER quantitative DNA methylation analysis of Runx3 P1 and P2 promoters of gastric 
tissues analysed for mRNA in panel (b). Histograms show the combined CpG methylation 
levels for P1 and P2, respectively. Error bars ± s.e.m. Asterisks show statistical significance: 
*P < 0.05; **P < 0.01; ***P<0.001. (e) Heatmaps show two-way hierarchical clustering of 
P1 and P2 individual CpG methylation values for data shown in panel (d).
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Figure 3. 
Immunolocalization of RUNX3 in human and murine gastric preneoplasia and 
tumorigenesis. (a) RUNX3 immunohistochemistry in human gastric mucosal tissue 
collected from H. pylori-infected and uninfected individuals. (b) Runx3 
immunohistochemistry in GmcsfTg gastric fundus. (c) Runx3 immunohistochemistry in 
gp130F/F gastric antral tumours. Tissue sections were counterstained with hematoxylin (blue 
staining). Magnifications are indicated (×20, ×40, ×100). Arrows indicate highly discrete 
Runx3 nuclear staining. lp, lamina propria; ep, epithelium.
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Figure 4. 
Differential Runx3 P1 methylation in GEC and hematopoietic lineages. (a) Isolation of 
immune cell populations from splenocytes by FACS: NK1.1+ CD3− NK cells; CD3+CD8+ 
T-cells; CD117+ FcεR1a+ MCs; CD11c+ DCs; CD11b+ macrophages; Gr1+ neutrophils; 
and CD45R+ B-cells. (b) QRT–PCR analysis of Runx3 P1 and P2 transcripts in FACS-
sorted immune cell types. Histograms show mRNA fold changes relative to levels in 
primary GEC. (c) Quantitative DNA methylation analysis of Runx3 P1 and P2 promoters in 
FACS-sorted immune cell types, primary GECs and primary mouse embryonic fibroblasts. 
Heatmap showing two-way hierarchical clustering of P1 and P2 methylation data. (d) In 
vitro generation of bone marrow-derived MCs. Flow cytometric analysis of murine bone 
marrow stem cells (BMSC) cultured with IL-3 (BMSC+IL3) or untreated (BMSC –ve). MC 
differentiation is shown by the acquisition of a CD117+ FcεR1+ double-positive phenotype 
(one representative experiment of four replicates is shown). (e) QRT–PCR analysis of Runx3 
P1 and P2 mRNA in BMSC+IL3 and BMSC control cultures. Error bars ± s.e.m. Asterisks 
show statistical significance: *P < 0.05. (f) Heatmap showing EpiTYPER quantitative 
methylation analysis of Runx3 P1 and P2 promoters corresponding to the samples analysed 
in panel (e).
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Figure 5. 
Runx3 P1 methylation in gastric tumour lineages. (a) Isolation of immune cells and GECs 
from gp130F/F gastric tumour tissue by FACS: CD8+ T-cells; CD11c+ DCs; and e-cadherin
+ GECs. Shown is one representative example of five replicate experiments. (b) EpiTYPER 
quantitative DNA methylation analysis of Runx3 P1 and P2 promoters of isolated cell types 
shown in panel (a). Histograms show the combined CpG methylation levels for P1 and P2, 
respectively. Error bars ± s.e.m. Asterisks show statistical significance: ***P < 0.001. (c) 
Heatmap showing two-way hierarchical clustering of P1 and P2 individual CpG methylation 
data represented in panel (b).
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Figure 6. 
RUNX3 P2 methylation is triggered by immortalization of human and mouse GECs. (a) 
EpiTYPER analysis of RUNX3 P2 (and P1) methylation levels in human GC cell lines, 
primary GC tumours and normal gastric epithelial tissues. Heatmap shows two-way 
hierarchical clustering of individual CpG methylation values against cell line or tissue type. 
(b) Flow diagram showing the derivation of mouse immortal GEC lines from gp130F/F 
primary gastric epithelial tumours. (c) Immunofluorescent detection of cytokeratin (Krt)8 in 
immortal GEC lines. Representative staining for one of the lines (clone 1) is shown. (d) 
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Growth curves of mouse immortal GEC lines in monolayer culture. Viable cell count data 
are shown as the mean of six replicate wells for each clone. (e) EpiTYPER analysis of 
Runx3 P1 and P2 methylation in immortal mouse GEC, primary gp130F/F tumours and WT 
gastric tissue. Heatmaps show two-way hierarchical clustering of individual CpG 
methylation values for P1 and P2.
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Figure 7. 
Schematic showing effects of cell-type composition and tumour clonality on RUNX3 
promoter methylation in GC progression and cell line establishment. In GECs, P1 is 
hypermethylated and repressed. In immune cells, P1 is hypomethylated and expressed (1). 
These lineage-specific differences in P1 methylation underlie P1 hypomethylation in GC 
progression (2). Immune cell recruitment triggered H. pylori infection (3), leads to altered 
cell-type composition of the gastric epithelium leading to decreased P1 methylation. 
Conversely, P2 lacks methylation in both GECs and immune cells, thus its methylation level 
is unaffected by altered tissue cellularity. In gastric tumours, P2 becomes aberrantly 
hypermethylated (in concert with other CGI promoters on a global scale) in a subset of 
highly immortalized/transformed GECs (orange shading), leading to a modest increase in P2 
methylation in tumour tissue (4). P2 hypermethylated clones have an in vitro growth 
advantage over non-hypermethylated clones, allowing their preferential expansion during 
cell line establishment from primary tumour tissue (5), leading to a significant over-
representation of P2 hypermethylated clones among GC cell lines (6).
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